{"id":"NCT01323647","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers","officialTitle":"Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (PoliorixTM) in Healthy Chinese Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-25","primaryCompletion":"2011-09-19","completion":"2011-09-19","firstPosted":"2011-03-25","resultsPosted":"2016-12-07","lastUpdate":"2019-02-11"},"enrollment":957,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"PoliorixTM","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix+Hib","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"ACTIVE_COMPARATOR"}],"summary":"This study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in the primary study. The study will also assess the immunogenicity and reactogenicity of a booster dose of IPV in subjects primed with three doses of IPV.","primaryOutcome":{"measure":"Number of Subjects Seroprotected for Poliovirus Types 1, 2 and 3 Antibodies Above the Cut-off Value","timeFrame":"One month after Poliorixâ„¢ booster vaccination.","effectByArm":[{"arm":"Poliorix Group","deltaMin":456,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":2,"countries":["China"]},"refs":{"pmids":["26873055"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":470},"commonTop":["Pyrexia","Irritability","Decreased appetite","Somnolence","Pain"]}}